Development of a method to quantify total and free irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) for pharmacokinetic and bio-distribution studies after administration of irinotecan liposomal formulation

Allen, 2013, Liposomal drug delivery systems: from concept to clinical applications, Adv Drug Deliv Rev, 65, 36, 10.1016/j.addr.2012.09.037 Passero, 2016, The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy, Expert Rev Anticancer Ther, 16, 697, 10.1080/14737140.2016.1192471 Drummond, 2006, Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy, Cancer Res, 66, 3271, 10.1158/0008-5472.CAN-05-4007 Charrois, 2004, Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer, Biochim Biophys Acta, 1663, 167, 10.1016/j.bbamem.2004.03.006 Mayer, 1995, Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques, Anal Biochem, 232, 149, 10.1006/abio.1995.0001 Thies, 1990, Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma, Anal Biochem, 188, 65, 10.1016/0003-2697(90)90528-H Deshpande, 2010, Determination of free and liposomal amphotericin B in human plasma by liquid chromatography-mass spectroscopy with solid phase extraction and protein precipitation techniques, J Chromatogr B Anal Technol Biomed Life Sci, 878, 315, 10.1016/j.jchromb.2009.11.036 Yamamoto, 2011, Direct, simultaneous measurement of liposome-encapsulated and released drugs in plasma by on-line SPE-SPE-HPLC, J Chromatogr B Anal Technol Biomed Life Sci, 879, 3620, 10.1016/j.jchromb.2011.10.004 Yang, 2013, Determination of free and total vincristine in human plasma after intravenous administration of vincristine sulfate liposome injection using ultra-high performance liquid chromatography tandem mass spectrometry, J Chromatogr A, 1275, 61, 10.1016/j.chroma.2012.12.026 Xie, 2017, Determination of non-liposomal and liposomal doxorubicin in plasma by LC-MS/MS coupled with an effective solid phase extraction: in comparison with ultrafiltration technique and application to a pharmacokinetic study, J Chromatogr B Anal Technol Biomed Life Sci, 1072, 149, 10.1016/j.jchromb.2017.11.020 Krishna, 2001, Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties, J Pharmacol Exp Ther, 298, 1206 Druckmann, 1989, Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies, Biochim et Biophys Acta, 980, 381, 10.1016/0005-2736(89)90329-5 Griese, 2002, Determination of free and liposome-associated daunorubicin and daunorubicinol in plasma by capillary electrophoresis, J Chromatogr A, 979, 379, 10.1016/S0021-9673(02)01440-1 Kim, 2010, Simultaneous analysis of liposomal doxorubicin and doxorubicin using capillary electrophoresis and laser induced fluorescence, J Pharmaceut Biomed Anal, 52, 372, 10.1016/j.jpba.2009.06.028 Wang, 2017, Development and validation of a UPLC-MS/MS assay for the determination of gemcitabine and its l-carnitine ester derivative in rat plasma and its application in oral pharmacokinetics, Asian J Pharmaceut Sci, 12, 478, 10.1016/j.ajps.2017.01.001 Fassberg, 1992, A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues, J Pharmaceut Sci, 81, 676, 10.1002/jps.2600810718 Burke, 1993, Preferential binding of the carboxylate form of camptothecin by human serum albumin, Anal Biochem, 212, 285, 10.1006/abio.1993.1325 https://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm603333.htm. Boyd, 2001, High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells, Anal Biochem, 297, 15, 10.1006/abio.2001.5317 Ramesh, 2010, Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives, Biomed Chromatogr: BMC, 24, 104, 10.1002/bmc.1345 Goldwirt, 2012, A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics, J Pharm Biomed Anal, 66, 325, 10.1016/j.jpba.2012.04.003 Zhang, 2009, An accurate assay for simultaneous determination of irinotecan and its active metabolite SN-38 in rat plasma by LC with fluorescence detection, Chromatographia, 70, 399, 10.1365/s10337-009-1161-5 Kurita, 1999, J Chromatogr B Biomed Sci Appl, 724, 335, 10.1016/S0378-4347(98)00554-4 Tsuji, 1991, CPT-11 converting enzyme from rat serum: purification and some properties, J Pharmacobio-Dyn, 14, 341, 10.1248/bpb1978.14.341